Global Leiomyosarcoma Drug
Global Leiomyosarcoma Drug

Leiomyosarcoma Drug Comprehensive Study by Type (AL-3818, BGB-290, C-21, Others), Application (Clinic, Hospital, Others), Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted drug therapy) Players and Region - Global Market Outlook to 2026

Leiomyosarcoma Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 216 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Leiomyosarcoma Drug Market Scope
Leiomyosarcoma is a type of cancer that begins in smooth muscle tissue. It starts in smooth muscle that lines organs like your stomach, bladder, and intestines. It is a broad category of cancers that begin in the tissues that connect, support, and surround other body structures. These drugs kill cancer cells but can also damage some normal cells. It depends on the location and stage of cancer. This cancer starts with common places such as the uterus, stomach, arms and legs, and small intestine.

The Leiomyosarcoma Drug market study is segmented by Type (AL-3818, BGB-290, C-21 and Others), by Application (Clinic, Hospital and Others) and major geographies with country level break-up.

Companies in the market are concentrating on the healthcare and pharmaceutical industry, focusing on developing drugs that will reduce the symptoms of Sarcoma. Multiple launches of new products during the forecast period, increased adoption of novel therapeutics, and the presence of key manufacturers in the U.S. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Leiomyosarcoma Drug market throughout the predicted period.

Advenchen Laboratories, LLC (United States), BeiGene, Ltd. (China), Cell Medica Limited (United Kingdom), Karyopharm Therapeutics, Inc. (United States), Merck and Co., Inc. (United States), Mirati Therapeutics Inc. (United States), Novartis AG (Switzerland) and Vicore Pharma AB (Europe) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Leiomyosarcoma Drug market by Type, Application and Region.

On the basis of geography, the market of Leiomyosarcoma Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

May 4, 2021: Vicore Pharma AB announce to sign the collaboration with Alex Therapeutics AB. This collaboration develops new digital therapeutic for the development and clinical validation for patients.


Market Trend
  • Increasing research and development activities

Market Drivers
  • The growth of abnormal cells and often grows quickly to invade and destroy normal body tissue
  • Rising incidence of sarcomas
  • Rapidly increase in costs of prescription drugs

Opportunities
  • Increased in the usage of bioabsorbable implants as alternatives to conventional synthetic implants

Restraints
  • Damaged normal cells

Challenges
  • Pain, weight loss, and a growing lump or swelling that can be felt through the skin


Key Target Audience
Healthcare Industry/Centres, Research & Development, Hospitals, Pharmaceutical Industries and Emerging Companies

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Leiomyosarcoma Drug Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • AL-3818
  • BGB-290
  • C-21
  • Others
By Application
  • Clinic
  • Hospital
  • Others
By Treatment
  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Targeted drug therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The growth of abnormal cells and often grows quickly to invade and destroy normal body tissue
      • 3.2.2. Rising incidence of sarcomas
      • 3.2.3. Rapidly increase in costs of prescription drugs
    • 3.3. Market Challenges
      • 3.3.1. Pain, weight loss, and a growing lump or swelling that can be felt through the skin
    • 3.4. Market Trends
      • 3.4.1. Increasing research and development activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Leiomyosarcoma Drug, by Type, Application, Treatment and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Leiomyosarcoma Drug (Value)
      • 5.2.1. Global Leiomyosarcoma Drug by: Type (Value)
        • 5.2.1.1. AL-3818
        • 5.2.1.2. BGB-290
        • 5.2.1.3. C-21
        • 5.2.1.4. Others
      • 5.2.2. Global Leiomyosarcoma Drug by: Application (Value)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Others
      • 5.2.3. Global Leiomyosarcoma Drug by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Radiation therapy
        • 5.2.3.3. Chemotherapy
        • 5.2.3.4. Targeted drug therapy
      • 5.2.4. Global Leiomyosarcoma Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Leiomyosarcoma Drug (Price)
      • 5.3.1. Global Leiomyosarcoma Drug by: Type (Price)
  • 6. Leiomyosarcoma Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Advenchen Laboratories, LLC (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BeiGene, Ltd. (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cell Medica Limited (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Karyopharm Therapeutics, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck and Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mirati Therapeutics Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Vicore Pharma AB (Europe)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Leiomyosarcoma Drug Sale, by Type, Application, Treatment and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Leiomyosarcoma Drug (Value)
      • 7.2.1. Global Leiomyosarcoma Drug by: Type (Value)
        • 7.2.1.1. AL-3818
        • 7.2.1.2. BGB-290
        • 7.2.1.3. C-21
        • 7.2.1.4. Others
      • 7.2.2. Global Leiomyosarcoma Drug by: Application (Value)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Others
      • 7.2.3. Global Leiomyosarcoma Drug by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Radiation therapy
        • 7.2.3.3. Chemotherapy
        • 7.2.3.4. Targeted drug therapy
      • 7.2.4. Global Leiomyosarcoma Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Leiomyosarcoma Drug (Price)
      • 7.3.1. Global Leiomyosarcoma Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Leiomyosarcoma Drug: by Type(USD Million)
  • Table 2. Leiomyosarcoma Drug AL-3818 , by Region USD Million (2015-2020)
  • Table 3. Leiomyosarcoma Drug BGB-290 , by Region USD Million (2015-2020)
  • Table 4. Leiomyosarcoma Drug C-21 , by Region USD Million (2015-2020)
  • Table 5. Leiomyosarcoma Drug Others , by Region USD Million (2015-2020)
  • Table 6. Leiomyosarcoma Drug: by Application(USD Million)
  • Table 7. Leiomyosarcoma Drug Clinic , by Region USD Million (2015-2020)
  • Table 8. Leiomyosarcoma Drug Hospital , by Region USD Million (2015-2020)
  • Table 9. Leiomyosarcoma Drug Others , by Region USD Million (2015-2020)
  • Table 10. Leiomyosarcoma Drug: by Treatment(USD Million)
  • Table 11. Leiomyosarcoma Drug Surgery , by Region USD Million (2015-2020)
  • Table 12. Leiomyosarcoma Drug Radiation therapy , by Region USD Million (2015-2020)
  • Table 13. Leiomyosarcoma Drug Chemotherapy , by Region USD Million (2015-2020)
  • Table 14. Leiomyosarcoma Drug Targeted drug therapy , by Region USD Million (2015-2020)
  • Table 15. South America Leiomyosarcoma Drug, by Country USD Million (2015-2020)
  • Table 16. South America Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 17. South America Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 18. South America Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 19. Brazil Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 20. Brazil Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 21. Brazil Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 22. Argentina Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 23. Argentina Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 24. Argentina Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 25. Rest of South America Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 27. Rest of South America Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 28. Asia Pacific Leiomyosarcoma Drug, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 32. China Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 33. China Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 34. China Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 35. Japan Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 36. Japan Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 37. Japan Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 38. India Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 39. India Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 40. India Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 41. South Korea Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 42. South Korea Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 43. South Korea Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 44. Taiwan Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 45. Taiwan Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 46. Taiwan Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 47. Australia Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 48. Australia Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 49. Australia Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 53. Europe Leiomyosarcoma Drug, by Country USD Million (2015-2020)
  • Table 54. Europe Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 55. Europe Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 56. Europe Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 57. Germany Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 58. Germany Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 59. Germany Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 60. France Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 61. France Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 62. France Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 63. Italy Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 64. Italy Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 65. Italy Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 66. United Kingdom Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 68. United Kingdom Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 69. Netherlands Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 70. Netherlands Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 71. Netherlands Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 72. Rest of Europe Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 73. Rest of Europe Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 74. Rest of Europe Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 75. MEA Leiomyosarcoma Drug, by Country USD Million (2015-2020)
  • Table 76. MEA Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 77. MEA Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 78. MEA Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 79. Middle East Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 80. Middle East Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 81. Middle East Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 82. Africa Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 83. Africa Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 84. Africa Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 85. North America Leiomyosarcoma Drug, by Country USD Million (2015-2020)
  • Table 86. North America Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 87. North America Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 88. North America Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 89. United States Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 90. United States Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 91. United States Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 92. Canada Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 93. Canada Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 94. Canada Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 95. Mexico Leiomyosarcoma Drug, by Type USD Million (2015-2020)
  • Table 96. Mexico Leiomyosarcoma Drug, by Application USD Million (2015-2020)
  • Table 97. Mexico Leiomyosarcoma Drug, by Treatment USD Million (2015-2020)
  • Table 98. Leiomyosarcoma Drug: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Leiomyosarcoma Drug: by Type(USD Million)
  • Table 108. Leiomyosarcoma Drug AL-3818 , by Region USD Million (2021-2026)
  • Table 109. Leiomyosarcoma Drug BGB-290 , by Region USD Million (2021-2026)
  • Table 110. Leiomyosarcoma Drug C-21 , by Region USD Million (2021-2026)
  • Table 111. Leiomyosarcoma Drug Others , by Region USD Million (2021-2026)
  • Table 112. Leiomyosarcoma Drug: by Application(USD Million)
  • Table 113. Leiomyosarcoma Drug Clinic , by Region USD Million (2021-2026)
  • Table 114. Leiomyosarcoma Drug Hospital , by Region USD Million (2021-2026)
  • Table 115. Leiomyosarcoma Drug Others , by Region USD Million (2021-2026)
  • Table 116. Leiomyosarcoma Drug: by Treatment(USD Million)
  • Table 117. Leiomyosarcoma Drug Surgery , by Region USD Million (2021-2026)
  • Table 118. Leiomyosarcoma Drug Radiation therapy , by Region USD Million (2021-2026)
  • Table 119. Leiomyosarcoma Drug Chemotherapy , by Region USD Million (2021-2026)
  • Table 120. Leiomyosarcoma Drug Targeted drug therapy , by Region USD Million (2021-2026)
  • Table 121. South America Leiomyosarcoma Drug, by Country USD Million (2021-2026)
  • Table 122. South America Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 123. South America Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 124. South America Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 125. Brazil Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 126. Brazil Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 127. Brazil Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 128. Argentina Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 129. Argentina Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 130. Argentina Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 131. Rest of South America Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 132. Rest of South America Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 133. Rest of South America Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 134. Asia Pacific Leiomyosarcoma Drug, by Country USD Million (2021-2026)
  • Table 135. Asia Pacific Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 136. Asia Pacific Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 137. Asia Pacific Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 138. China Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 139. China Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 140. China Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 141. Japan Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 142. Japan Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 143. Japan Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 144. India Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 145. India Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 146. India Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 147. South Korea Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 148. South Korea Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 149. South Korea Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 150. Taiwan Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 151. Taiwan Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 152. Taiwan Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 153. Australia Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 154. Australia Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 155. Australia Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 159. Europe Leiomyosarcoma Drug, by Country USD Million (2021-2026)
  • Table 160. Europe Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 161. Europe Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 162. Europe Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 163. Germany Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 164. Germany Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 165. Germany Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 166. France Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 167. France Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 168. France Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 169. Italy Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 170. Italy Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 171. Italy Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 172. United Kingdom Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 173. United Kingdom Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 174. United Kingdom Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 175. Netherlands Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 176. Netherlands Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 177. Netherlands Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 178. Rest of Europe Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 179. Rest of Europe Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 180. Rest of Europe Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 181. MEA Leiomyosarcoma Drug, by Country USD Million (2021-2026)
  • Table 182. MEA Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 183. MEA Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 184. MEA Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 185. Middle East Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 186. Middle East Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 187. Middle East Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 188. Africa Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 189. Africa Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 190. Africa Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 191. North America Leiomyosarcoma Drug, by Country USD Million (2021-2026)
  • Table 192. North America Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 193. North America Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 194. North America Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 195. United States Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 196. United States Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 197. United States Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 198. Canada Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 199. Canada Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 200. Canada Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 201. Mexico Leiomyosarcoma Drug, by Type USD Million (2021-2026)
  • Table 202. Mexico Leiomyosarcoma Drug, by Application USD Million (2021-2026)
  • Table 203. Mexico Leiomyosarcoma Drug, by Treatment USD Million (2021-2026)
  • Table 204. Leiomyosarcoma Drug: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Leiomyosarcoma Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Leiomyosarcoma Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Leiomyosarcoma Drug: by Treatment USD Million (2015-2020)
  • Figure 7. South America Leiomyosarcoma Drug Share (%), by Country
  • Figure 8. Asia Pacific Leiomyosarcoma Drug Share (%), by Country
  • Figure 9. Europe Leiomyosarcoma Drug Share (%), by Country
  • Figure 10. MEA Leiomyosarcoma Drug Share (%), by Country
  • Figure 11. North America Leiomyosarcoma Drug Share (%), by Country
  • Figure 12. Global Leiomyosarcoma Drug: by Type USD/Units (2015-2020)
  • Figure 13. Global Leiomyosarcoma Drug share by Players 2020 (%)
  • Figure 14. Global Leiomyosarcoma Drug share by Players (Top 3) 2020(%)
  • Figure 15. Global Leiomyosarcoma Drug share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Advenchen Laboratories, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 18. Advenchen Laboratories, LLC (United States) Revenue: by Geography 2020
  • Figure 19. BeiGene, Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 20. BeiGene, Ltd. (China) Revenue: by Geography 2020
  • Figure 21. Cell Medica Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Cell Medica Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Karyopharm Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Karyopharm Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Merck and Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck and Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Mirati Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mirati Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 31. Vicore Pharma AB (Europe) Revenue, Net Income and Gross profit
  • Figure 32. Vicore Pharma AB (Europe) Revenue: by Geography 2020
  • Figure 33. Global Leiomyosarcoma Drug: by Type USD Million (2021-2026)
  • Figure 34. Global Leiomyosarcoma Drug: by Application USD Million (2021-2026)
  • Figure 35. Global Leiomyosarcoma Drug: by Treatment USD Million (2021-2026)
  • Figure 36. South America Leiomyosarcoma Drug Share (%), by Country
  • Figure 37. Asia Pacific Leiomyosarcoma Drug Share (%), by Country
  • Figure 38. Europe Leiomyosarcoma Drug Share (%), by Country
  • Figure 39. MEA Leiomyosarcoma Drug Share (%), by Country
  • Figure 40. North America Leiomyosarcoma Drug Share (%), by Country
  • Figure 41. Global Leiomyosarcoma Drug: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Advenchen Laboratories, LLC (United States)
  • BeiGene, Ltd. (China)
  • Cell Medica Limited (United Kingdom)
  • Karyopharm Therapeutics, Inc. (United States)
  • Merck and Co., Inc. (United States)
  • Mirati Therapeutics Inc. (United States)
  • Novartis AG (Switzerland)
  • Vicore Pharma AB (Europe)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation